Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Jan 14, 2026, 17:31 ET

      Share this article

      Share this article


      The house dust mite disease market is experiencing steady growth, driven by rising global prevalence of allergic rhinitis and asthma linked to indoor allergens. Increasing adoption of allergen-specific immunotherapies, including sublingual tablets, is expanding treatment options and fueling market demand. Additionally, the launch of emerging therapies such as HAL Allergy's PURETHAL Mites, Probelte Pharma's BELTAVAC, Inmunotek's MM09, T-Balance Therapeutics' tregalizumab, and others will further drive the market forward.

      LAS VEGAS, Jan. 14, 2026 /PRNewswire/ -- DelveInsight's House Dust Mite Disease Market Insights report includes a comprehensive understanding of current treatment practices, house dust mite disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China]. 

      House Dust Mite Disease Market Summary

      • The market size for house dust mite disease was found to be USD 9.2 billion in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China] in 2024.
      • China accounts for the largest market size for HDMD, compared with the United States, EU4, the UK, and Japan, i.e., ~35% of the 7MM + China.
      • In 2024, the prevalent population of HDMD was estimated at 40 million cases. This prevalence is influenced by widespread exposure to HDM in indoor environments, increasing rates of atopy, urbanization, and changing lifestyles that favour prolonged indoor activities.
      • Leading house dust mite disease companies, such as HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics, and others, are developing new house dust mite disease treatment drugs that can be available in the house dust mite disease market in the coming years. 
      • The promising house dust mite disease therapies in clinical trials include House dust mite allergy vaccine (PURETHAL Mites), Alternaria allergy immunotherapy (BELTAVAC), MM09, Tregalizumab, and others.

      Discover the new house dust mite disease treatment @ https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

      Key Factors Driving the Growth of the House Dust Mite Disease Market 

      • Rising Asthma Burden: In 2024, the diagnosed prevalent population of asthma in the 7MM was approximately 113 million. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
      • Current Sublingual Immunotherapy Options for Allergic Rhinitis: Currently, ODACTRA (ALK-Abelló) and ACTAIR (Stallergenes Greer) are the only available treatments that use a similar way of administration. Both products are well-established options for sublingual allergen immunotherapy in patients with allergic rhinitis.
      • Mid- to Late-Stage HDM Therapies: Few late- and mid-stage therapies, such as PURETHAL Mites, BELTAVAC, MM09, and tregalizumab, are being evaluated for HDM-induced allergic rhinitis; however, the absence of recent clinical progress, limited efficacy and safety data, and a lack of advanced-stage results make their therapeutic potential and regulatory prospects uncertain relative to established products.
      • Tregalizumab: A Differentiated Treg-Targeted Asset: Tregalizumab, developed by T-Balance Therapeutics, uniquely activates Tregs with high specificity and a well-defined pharmacokinetic profile, underscoring its innovative therapeutic potential.

      House Dust Mite Disease Market Analysis

      • Management of HDMD is largely centered on symptomatic relief using off-label and supportive therapies, reflecting the lack of approved disease-modifying treatments.
      • Common treatment options include antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and allergen immunotherapy (AIT).
      • While AIT remains a cornerstone of care, its clinical efficacy varies significantly among patients.
      • Long treatment durations, suboptimal adherence, and safety concerns, such as the risk of systemic allergic reactions, often limit the real-world utility of AIT.
      • The HDMD therapeutic landscape is gradually evolving with the development of targeted immunotherapies and peptide-based vaccines designed to induce immune tolerance while minimizing adverse effects.
      • The approval of ODACTRA marked a key milestone as the first sublingual immunotherapy tablet for HDM-induced allergic rhinitis; however, its black-box warning and limited pediatric safety data highlight ongoing challenges in long-term disease control.
      • Several late-stage candidates, including PURETHAL Mites, BELTAVAC, and MM09, are in development, though publicly available updates are limited, indicating modest recent developmental momentum.
      • None of these assets has advanced to regulatory submission or commercialization, leaving timelines to market uncertain.
      • Tregalizumab, currently in mid-stage development, represents a differentiated approach by selectively activating regulatory T cells (Tregs) and is supported by well-characterized pharmacokinetic data, positioning it as a potentially innovative therapy in HDMD.

      House Dust Mite Disease Competitive Landscape

      The emerging pipeline of HDMD holds a few products in development by prominent key players such as HAL Allergy (PURETHAL Mites), Probelte Pharma (BELTAVAC), Inmunotek (MM09), T-Balance Therapeutics (tregalizumab), and others.

      HAL Allergy's PURETHAL Mites is a subcutaneous allergen immunotherapy that employs a chemically modified house dust mite (HDM) extract, Dermatophagoides pteronyssinus and Dermatophagoides farinae, adsorbed onto aluminum hydroxide. The therapy is currently being evaluated in a Phase III clinical trial.

      Probelte Pharma's BELTAVAC is a subcutaneous immunotherapy indicated for the treatment of Alternaria mold allergy. Developed by Probelte Pharma, it is a safer allergen immunotherapy based on a Dermatophagoides pteronyssinus dust mite extract that has been chemically altered through glutaraldehyde polymerization. This product is also in Phase III clinical development.

      The anticipated launch of these emerging therapies are poised to transform the house dust mite disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the house dust mite disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about the house dust mite disease drugs @ House Dust Mite Disease Drugs Market 

      Recent Developments in the House Dust Mite Disease Market

      • In September 2025, Stallergenes Greer and Nuance Pharma entered into an exclusive long-term partnership to develop and commercialize ACTAIR, Stallergenes Greer's sublingual allergen immunotherapy tablet for the treatment of HDM-induced allergic rhinitis.
      • In July 2025, Stallergenes Greer and CEOLIA Pharma announced the transition of promotional activities for ACTAIR in Japan. After ending the 2010 license agreement with Shionogi, which had been responsible for developing, registering, and commercializing ACTAIR in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country, effective July 3.
      • In February 2025, the US FDA approved ALK's ODACTRA tablet for use in young children with HDM allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged 5–11 years, in addition to patients aged 12 through 65.

      What is House Dust Mite Disease?

      House dust mite disease (HDMD) is a chronic allergic condition caused by an immune hypersensitivity to proteins found in the feces and body fragments of house dust mites. These microscopic arthropods thrive in indoor environments, including bedding, carpets, and upholstered furniture. In sensitized individuals, exposure to these allergens triggers an IgE-mediated inflammatory response, leading to symptoms that commonly affect the upper and lower airways, including allergic rhinitis, nasal congestion, sneezing, itchy or watery eyes, chronic cough, and asthma exacerbations. HDMD is a major contributor to perennial allergic respiratory disease worldwide, with symptoms often persisting year-round due to continuous indoor exposure, significantly impacting quality of life, sleep, productivity, and long-term respiratory health.

      House Dust Mite Disease Epidemiology Segmentation

      The house dust mite disease epidemiology section provides insights into the historical and current house dust mite disease patient pool and forecasted trends for the leading markets. HDM allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations, which report a prevalence of only 50 to 70%.

      The house dust mite disease treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Total Prevalent Population of HDMD  
      • Total Diagnosed Prevalent Population of HDMD 
      • Gender-specific Diagnosed Prevalent Population of HDMD
      • Allergen-specific Diagnosed Prevalent Population of HDMD
      • Total Treated Cases of HDMD

      House Dust Mite Disease Market Report Metrics

      Details

      Study Period

      2020–2034

      Coverage

      8MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China].

      House Dust Mite Disease Market CAGR

      3.5 %

      House Dust Mite Disease Market Size in 2024

      USD 9.2 Billion

      Key House Dust Mite Disease Companies

      HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics, ALK-Abello, Stallergenes Greer, and others

      Key House Dust Mite Disease Therapies

      House dust mite allergy vaccine (PURETHAL Mites), Alternaria allergy immunotherapy (BELTAVAC), MM09, Tregalizumab, ODACTRA/ACARIZAX/MITICURE, ACTAIR/ORYLMYTE/AITMYTE, and others

      Scope of the House Dust Mite Disease Market Report

      • Therapeutic Assessment: House Dust Mite Disease current marketed and emerging therapies
      • House Dust Mite Disease Market Dynamics: Key Market Forecast Assumptions of Emerging House Dust Mite Disease Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, House Dust Mite Disease Market Access and Reimbursement

      Download the report to understand what is the latest research on house dust mite disease @ New House Dust Mite Disease Medication 

      Table of Contents

      1

      House Dust Mite Disease Market Key Insights

      2

      House Dust Mite Disease Market Report Introduction

      3

      Executive Summary of HDMD

      4

      Key Events

      5

      Epidemiology and Market Forecast Methodology

      6

      HDMD Market Overview at a Glance

      6.1

      Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])

      6.2

      Market Share of HDMD by Therapies (%) in the 7MM + China in 2024

      6.3

      Market Share of HDMD by Therapies (%) in the 7MM + China in 2034

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      House Dust Mite Allergic Disorders

      7.2.1

      Allergic Asthma

      7.2.2

      Allergic Rhinitis

      7.2.3

      Atopic Dermatitis

      7.3

      Symptoms

      7.4

      Diagnosis

      8

      House Dust Mite Disease Treatment

      9

      Epidemiology and Patient Population

      9.1

      Key Findings

      9.2

      Assumptions and Rationales

      9.3

      Total Diagnosed Prevalent Population of Asthma in the 7MM + China

      9.4

      Total Diagnosed Prevalent Population of Allergic Rhinitis in the 7MM + China

      9.5

      Total Diagnosed Prevalent Population of Atopic Dermatitis in the 7MM + China

      9.6

      Total Diagnosed Prevalent Population of HDMD in the 7MM + China

      9.7

      The United States

      9.7.1

      Total Prevalent Population of HDMD in the United States

      9.7.2

      Total Diagnosed Prevalent Population of HDMD in the United States

      9.7.3

      Gender-specific Diagnosed Prevalent Population of HDMD in the United States

      9.7.4

      Allergen-specific Diagnosed Prevalent Population of HDMD in the United States

      9.7.5

      Total Treated Cases of HDMD in the United States

      9.8

      EU4 and the UK

      9.9

      Japan

      9.10

      China

      10

      House Dust Mite Disease Patient Journey

      11

      Marketed House Dust Mite Disease Drugs

      11.1

      Key Cross Competition

      11.2

      Dermatophagoides farinae and Dermatophagoides pteronyssinus (ODACTRA/ACARIZAX/MITICURE): ALK-Abello

      11.2.1

      Product Description

      11.2.2

      Regulatory Milestones

      11.2.3

      Other Developmental Activities

      11.2.4

      Summary of Pivotal Trials

      11.2.5

      Clinical Development

      11.2.6

      Analyst Views

      11.3

      House dust mite allergen extract (ACTAIR/ORYLMYTE/AITMYTE): Stallergenes Greer

      12

      Emerging House Dust Mite Disease Drugs

      12.1

      Key Cross Competition

      12.2

      House Dust Mite Allergy Vaccine (PURETHAL Mites): HAL Allergy

      12.2.1

      Product Description

      12.2.2

      Clinical Development

      12.3

      Alternaria Allergy Immunotherapy (BELTAVAC): Probelte Pharma

      12.4

      MM09: Inmunotek

      12.5

      Tregalizumab: T-Balance Therapeutics

      13

      HDMD Market: 7MM + China Analysis

      13.1

      Key Findings

      13.2

      Total Market Size of HDM in the 7MM + China

      13.3

      House Dust Mite Disease Market Outlook

      13.4

      Conjoint Analysis

      13.5

      Key House Dust Mite Disease Market Forecast Assumptions

      13.6

      The United States House Dust Mite Disease Market Size

      13.6.1

      Total Market Size of HDMD in the United States

      13.6.2

      Total Market Size of HDMD by Therapies in the United States

      13.7

      EU4 and the UK House Dust Mite Disease Market Size

      13.8

      Japan House Dust Mite Disease Market Size

      13.9

      China House Dust Mite Disease Market Size

      14

      House Dust Mite Disease Market Unmet Needs

      15

      House Dust Mite Disease Market SWOT Analysis

      16

      KOL Views on House Dust Mite Disease 

      17

      House Dust Mite Disease Market Access and Reimbursement

      17.1

      The United States

      17.2

      In EU4 and the UK

      17.3

      Japan

      17.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      17.5

      Market Access and Reimbursement of HDMD Therapies

      18

      Bibliography

      19

      House Dust Mite Disease Market Report Methodology

      Related Reports

      Asthma Market

      Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, Areteia Therapeutics, Sanofi, Connect Biopharma, Upstream Bio, Teva Pharmaceuticals, Launch Therapeutics, AstraZeneca, Incyte Corporation, among others.

      Severe Asthma Market

      Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe asthma companies including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, among others.

      Allergic Rhinitis Market

      Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key allergic rhinitis companies including Inmunotek, Emergo Therapeutics, AOBiome LLC, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Allergy Therapeutics, among others.

      Atopic Dermatitis Market

      Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]  
      +14699457679
      www.delveinsight.com 

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.